Enhancing Target Tissue Levels and Diminishing Plasma Clearance of Ionizing Zwitterionic Antidotes in Organophosphate Exposures
- 18 June 2021
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 378 (3), 315-321
- https://doi.org/10.1124/jpet.121.000715
Abstract
Inhibition of acetylcholinesterase (AChE) by certain organophosphates (OPs) can be life-threatening and requires reactivating antidote accessibility to the peripheral and central nervous systems to reverse symptoms and enhance survival parameters. In considering dosing requirements for oxime antidotes in OP exposures that inactivate AChE, clearance of proton ionizable, zwitterionic antidotes is rapid and proceeds with largely the parent antidotal compound being cleared by renal transporters. Such transporters may also control disposition between target tissues and plasma as well as overall elimination from the body. An ideal small-molecule antidote should access and be retained in primary target tissues—central nervous system (brain), skeletal muscle, and peripheral autonomic sites—for sufficient periods to reactivate AChE and prevent acute toxicity. We show here that we can markedly prolong the antidotal activity of zwitterionic antidotes by inhibiting P-glycoprotein (P-gp) transporters in the brain capillary and renal systems. We employ the P-gp inhibitor tariquidar as a reference compound and show that tissue and plasma levels of RS194B, a hydroxyl-imino acetamido alkylamine reactivator, are elevated and that plasma clearances are reduced. To examine the mechanism, identify the transporter, and establish the actions of a transport inhibitor, we compare the pharmacokinetic parameters in a P-glycoprotein knockout mouse strain and see dramatic enhancements of short-term plasma and tissue levels. Hence, repurposed transport inhibitors that are candidate or Food and Drug Administration–approved drugs, should enhance target tissue concentrations of the zwitterionic antidote through inhibition of both renal elimination and brain capillary extrusion. SIGNIFICANCE STATEMENT We examine renal and brain capillary transporter inhibition as means for lowering dose and frequency of dosing of a blood-brain barrier permanent reactivating antidote, RS194B, an ionizable zwitterion. Through a small molecule, tariquidar, and gene knockout mice, CNS antidote concentrations are enhanced, and total body clearances are concomitantly diminished. RS194B with repurposed transport inhibitors should enhance reactivation of central and peripheral OP-inhibited acetylcholinesterase. Activities at both disposition sites are a desired features for replacing the antidote, pralidoxime, for acute OP exposure.This publication has 34 references indexed in Scilit:
- OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesBritish Journal of Pharmacology, 2012
- Brain penetration of ivermectin and selamectin inmdr1a,bP‐glycoprotein‐ andbcrp‐ deficient knockout miceJournal of Veterinary Pharmacology and Therapeutics, 2009
- Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PETJournal of Nuclear Medicine, 2008
- Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit?BJU International, 2006
- Efflux transport systems for organic anions and cations at the blood–CSF barrierAdvanced Drug Delivery Reviews, 2004
- Increased Splenic Capacity in Response to Transdermal Application of Nitroglycerine in the DogJournal of Veterinary Internal Medicine, 1999
- Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugsChemico-Biological Interactions, 1993
- TARGET SITES FOR ANTICHOLINESTERASES ON THE VENTRAL SURFACE OF THE MEDULLA OBLONGATA: HYPOTENSION ELICITED BY ORGANOPHOSPHORUS AGENTSJournal of Autonomic Pharmacology, 1986
- Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequenceNature, 1986
- Cardiovascular Control by Cholinergic Mechanisms in the Central Nervous SystemAnnual Review of Pharmacology and Toxicology, 1982